Shorter radiation course stops cancer growth in high-risk prostate cancer patients

	Tweet

Hypofractionated radiation treatment, a newer type of radiation treatment that delivers higher doses of radiation in fewer treatments than conventional radiation therapy, is significantly more effective in stopping cancer from growing in high risk patients, compared to receiving standard radiation treatment, according to a study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO). In addition, findings show there is no increased risk of negative side effects later in patients who undergo hypofractionated radiation.

“The study not only shows that hypofractionated radiation improves the control of prostate cancer, but it also cuts the number of treatment visits in half for patients. This is an important benefit for these high-risk patients, who are typically an older, less mobile population,” Giorgio Arcangeli, M.D., lead author of the study and a radiation oncologist at the Regina Elena National Cancer Institute in Rome, Italy said. “It’s also especially helpful for those living at long distance from radiation treatment centers.”

All men in the study were treated with three-dimensional conformal radiation therapy, or 3D-CRT. It is a type of external beam radiation therapy that uses computers and special imaging techniques to show the size, shape and location of the tumor as well as surrounding organs to precisely tailor the radiation beams to the size and shape of the tumor. Because the radiation beams are very precisely directed, nearby normal tissue receives less radiation and is able to heal more quickly. 

During external beam radiation therapy, a beam of radiation is directed through the skin to the cancer and the immediate surrounding area in order to destroy the main tumor and any nearby cancer cells.

From January 2003 to December 2007, a total of 168 high risk prostate cancer patients were randomized to receive either hypofractionated or conventional schedules of 3D-CRT to the prostate and surrounding area. Patients who received hypofractionated radiation had only 20 sessions of radiation (four weeks of daily radiation therapy treatments), instead of the 40 to 45 (eight to nine weeks of daily treatments) sessions typically required during standard radiation treatment.

Study findings show that the patients treated with hypofractionated radiation had a better chance (87 percent vs. 79 percent) that their cancer would stop growing, compared to patients treated with standard radiation therapy. There was also no difference in the late side effects of genito-urinary and gastro-intestinal function between the two groups of patients.

“Studies are in progress to test the benefits of even shorter treatment schedules,” Dr. Arcangeli said.

###

For more information on radiation therapy for prostate cancer, visit http://www.rtanswers.org.

The abstract, “A Phase III Randomized Study Of High Dose Conventional Vs Hypofractionated Radiotherapy In Patients With High Risk Prostate Cancer,” will be presented at a scientific session at 11:00 a.m. on Wednesday, November 4, 2009. To speak to the lead author of the study, Giorgio Arcangeli, M.D., please call Beth Bukata or Nicole Napoli November 1-4, 2009, in the ASTRO Press Room at McCormick Place West at 312-791-7005 or 312-791-7006. You may also e-mail them at or .

---
Contact: Beth Bukata

703-474-0940
American Society for Radiation Oncology

RELATED STORIES:
Gonorrhea linked to higher prostate cancer risk   Prostate cancer therapy linked to increased risk of heart disease death   Men often not told of prostate cancer risks: study   Barbecue meats linked with prostate cancer   Hops Compound May Prevent Prostate Cancer   New, Non-invasive Prostate Cancer Test Beats PSA in Detecting Prostate Cancer   Many men struggle to work after prostate cancer   Urine test may detect aggressive prostate tumors   Guide aims to help men understand prostate cancer   Carcinoma of the Prostate (CAP)   Radiation added to hormone therapy increases survival for men with prostate cancer   ‘Statins’ improve prostate cancer outcome   Common painkillers lower levels of prostate cancer biomarker   Laser may reduce prostate surgery’s sexual side effects   Diet May Reduce Risk of Prostate Cancer   Researchers find prostate cancer stem cell   No risk seen from delaying prostate cancer surgery   Biofeedback cuts urine leak after prostate surgery   Model of Prostate Cancer Helps Identify Promising Pain Treatment   Delaying therapy OK for low-risk prostate cancer   Gleevec strangles drug-resistant, metastatic prostate cancer   New data show benefit of finasteride in preventing prostate cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]